Funded Biotechnology Startups in Irvine
17 funded biotechnology startups in irvine — recent funding rounds, disclosed amounts, and headquarters. Updated weekly, free to browse.
The disclosed-round size distribution is highly top-heavy. The largest disclosed amount in this Irvine biotech set is $250M for NXT Biomedical (Seed, 2022-08-09), which is substantially above the next-largest disclosed rounds ($125M for Tarsus Pharmaceuticals on 2025-03-12 and Evolus on 2021-12-14). At the low end, the smallest disclosed amount is $250K for NXT Biomedical (2022-08-09).
Temporal clustering is visible despite some spread: the rows span 2020-12-29 (AiVita Biomedical) through 2026-06-10 (ThruFlo Endovascular). Most entries are labeled “Series Unknown” (5 of 17 rows), and disclosed amounts concentrate in the $7M–$40M band (for example Biolase at $7M on 2024-02-13; MDxHealth at $40M on 2024-09-25), with a notable outlier at $125M (Tarsus) and another at $120M (CG Oncology on 2022-11-15).
Most recent rounds
17 shownRelated listings
Frequently asked
Which round appears to be the size outlier in this Irvine biotechnology slice, and how far above the rest is it based on disclosed figures?
NXT Biomedical’s disclosed $250M Seed round on 2022-08-09 is the clear outlier here; the next-largest disclosed amounts shown are $125M for Tarsus Pharmaceuticals (2025-03-12) and $125M for Evolus (2021-12-14).
How many entries fall into the most recent 12 months of the displayed list, and what are the notable sizes?
From 2025-07-11 to 2026-07-11, four rows appear: ThruFlo Endovascular (undisclosed, 2026-06-10), Restora Medical ($12M, 2026-05-29), and Tarsus Pharmaceuticals ($125M, 2025-03-12) plus PeproMene Bio ($11M, 2024-12-18) are outside that window, so the only disclosed sizes in the most recent-year window shown are $12M (Restora Medical) alongside undisclosed activity (ThruFlo).
Is the round labeling concentrated in any stage/metadata bucket, such as “Series Unknown” or “undisclosed”?
Yes: “Series Unknown” appears on 5 of 17 rows (including Tarsus Pharmaceuticals on 2025-03-12 and MDxHealth on 2024-09-25). “Undisclosed” appears on 2 of 17 rows (ThruFlo Endovascular on 2026-06-10; Matregenix on 2022-09-01).
Do most disclosed rounds cluster in a narrow funding range, or are there multiple distinct bands?
There’s noticeable clustering in the mid-range: $7M–$40M includes Biolase ($7M, 2024-02-13), University Lab Partners ($2M, 2023-11-09), OncoCyte ($14M, 2023-04-03), Biomerica ($8M, 2023-03-03), PeproMene Bio ($11M, 2024-12-18), Immunis ($16M, 2024-07-01), MDxHealth ($40M, 2024-09-25), and CG Oncology ($120M, 2022-11-15) sits above that band.
What stage/structure pattern stands out among non-“Series Unknown” entries in this list?
A mix of specific labels appears, but the largest disclosed amounts align with a subset of structured entries: NXT Biomedical is labeled Seed with $250M (2022-08-09), while CG Oncology is labeled Series E with $120M (2022-11-15). By contrast, post-market classifications are smaller in this set: Hancock Jaffe Laboratories shows Post-IPO Equity at $20M (2021-09-07) and Evolus shows Post-IPO Debt at $125M (2021-12-14).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.